Journal of Young Pharmacists is a distinguished peer-reviewed journal published by INPHARM ASSOCIATION in collaboration with PHCOG NET. With an ISSN of 0975-1483 and an E-ISSN of 0975-1505, this journal serves as a vital platform for disseminating pioneering research in the field of pharmacology and toxicology. Although coverage in Scopus was discontinued in 2018, the journal continues to be important in educating future pharmacists and advancing the discipline, evident from its ranking in the 29th percentile among general pharmacology journals. The Journal of Young Pharmacists seeks to bridge the gap between theoretical knowledge and practical application, encouraging young researchers, professionals, and students to contribute their insights and findings. The journal emphasizes innovative approaches and contemporary issues relevant to the pharmaceutical sciences, making it an invaluable resource for anyone involved in this dynamic field.

VALUE IN HEALTH, published by Elsevier Science Inc, is a premier peer-reviewed journal in the fields of Health Policy, Medicine, and Public Health. With an impressive impact factor reflecting its respected standing, the journal has achieved a distinguished Q1 classification in multiple categories, placing it among the top publications in the health domain. Since its inception in 1998, this journal has been a vital platform for disseminating research that informs health policy and practice, impacting both clinical and public health decision-making. The journal’s Scopus rankings further underscore its global influence, with notable positions in Medicine and Public Health sectors. VALUE IN HEALTH is committed to fostering an environment where innovative research meets practical application, ultimately aiming to enhance health outcomes worldwide. Researchers, professionals, and students alike are encouraged to explore the wealth of knowledge contained within its pages.

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

Rheumatology and Therapy, published by Springer, stands as a prominent open-access journal within the fields of Immunology and Allergy and Rheumatology. Since its inception in 2014, the journal has made significant contributions to advancing the understanding, diagnosis, and treatment of rheumatic diseases, garnering a solid reputation with an impact factor that reflects its rigorous peer-review process and scholarly influence. Currently ranked in the Q2 quartile for both its categories according to 2023 metrics, it occupies a significant position among its peers, standing at Rank #21 out of 73 in Medicine Rheumatology and Rank #101 out of 233 for Medicine Immunology and Allergy. The journal's scope encompasses cutting-edge research, reviews, and clinical studies that aim to bridge the gap between laboratory findings and patient care, making it an invaluable resource for researchers, clinicians, and students alike. With its commitment to open access, Rheumatology and Therapy ensures that high-quality research is available to a global audience, fostering collaboration and innovation in rheumatology and immunology. To learn more, visit their official site and explore the wealth of knowledge available.

Farmeconomia-Health Economics and Therapeutic Pathways is a pioneering journal within the field of health economics, dedicated to exploring the intersections of health policy, therapeutics, and economic evaluations. Published by SEED MEDICAL PUBLISHERS, this Open Access journal has been at the forefront of advancing knowledge since 2012, ensuring that vital research is readily accessible to a global audience without subscription barriers. The journal aims to facilitate the dissemination of insightful studies, systematic reviews, and theoretical discussions that determine the cost-effectiveness of therapeutic options, ultimately guiding evidence-based healthcare decisions. Based in *Torino, Italy*, this journal is committed to serving researchers, healthcare professionals, and students who are eager to contribute to and stay updated on the latest developments in health economics and policy implementation. With its broad-ranging scope and dedication to quality research, Farmeconomia stands as an essential resource for anyone engaged in the complex dynamics of health systems and their economic implications.

ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.

The Journal of Managed Care & Specialty Pharmacy is a premier publication in the realm of health policy and pharmaceutical science, dedicated to enhancing the understanding and practices surrounding managed care systems and specialty medications. Published by ACAD MANAGED CARE PHARMACY, this journal boasts an impressive Q1 ranking in both Pharmaceutical Science and Pharmacy, underscoring its significance in advancing professional discourse and research in these critical areas. With a focus on innovative care strategies and patient-centered approaches, it aims to share impactful research, reviews, and opinions that shape the future of health policy and pharmaceutical practices. The journal is available in an open access format, ensuring that vital information is universally accessible to researchers, practitioners, and policymakers alike. With its inception in 2014 and an ongoing commitment to excellence through 2024, the journal is firmly established as a leading resource within its field, making it essential reading for professionals dedicated to improving managed care and specialty pharmacy solutions.

Current Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.